FDA Brief

Warning letters Devices

FDA warning letter to

Pro-Optics, LLC

MediumIssued Oct 5Posted Oct 27Center for Devices and Radiological Health

FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

What happened

FDA inspected Pro-Optics in Palatine, Illinois, from March 3, 2026 through March 11, 2026, and reviewed its website. FDA found the firm changed polymers and colorants in its Tight Top and Flip Top contact lens cases without a new premarket notification, and lacked design and change-control records.

What FDA found

  1. FDA says the contact lens cases are adulterated because the firm lacks an approved premarket approval or investigational device exemption.

    section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)
  2. FDA says the firm did not notify FDA before commercially distributing changed devices, making them misbranded.

    section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 C.F.R. 807.81(a)(3)(i)
  3. The firm changed polymers and colorants from those cleared under K875197, including adding uncleared colors, without FDA review.

    21 C.F.R. 807.81(a)(3)(i)
  4. The firm had no documented design and development procedures or records.

    ISO 13485:2016, Clause 7.3.1; 21 C.F.R. Part 820
  5. The firm did not document or evaluate the change from one contract manufacturer to another.

    ISO 13485:2016, Clause 4.1.4; 21 C.F.R. Part 820

What FDA wants

FDA asks Pro-Optics to respond in writing within 15 business days with the specific steps taken to correct the violations, documentation of systemic fixes, and a timetable for any longer-term actions; if it believes products are not in violation, it must include reasoning and supporting information.

Who should pay attention

  • distributors and retailers selling contact lens cases
  • private-label brands sourcing molded device components
  • device firms relying on 510(k) clearances and design-change records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk
  4. Specialty Health Products CO, LLC

    Specialty Health Products was cited for quality-system, unapproved marketing, and listing violations for its Hydro-San and Aqua Cleanse colonic irrigation devices.

    High risk